{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:59:18Z","timestamp":1781121558171,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of the study was to benchmark and compare breast cancer care quality indicators (QIs) between Norway and the Netherlands using federated analytics preventing transfer of patient-level data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Breast cancer patients (2017\u20132018) were retrieved from the Netherlands Cancer Registry and the Cancer Registry of Norway. Five European Society of Breast Cancer Specialists (EUSOMA) QIs were assessed: two on magnetic resonance imaging (MRI), two on surgical approaches, and one on postoperative radiotherapy. The QI outcomes were calculated using \u2018Vantage 6\u2019 federated Propensity Score Stratification (PSS). Likelihood of receiving a treatment was expressed in odds ratios (OR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 39,163 patients were included (32,786 from the Netherlands and 6377 from Norway). PSS scores were comparable to the crude outcomes of the QIs. The Netherlands scored higher on the QI \u2018proportions of patients preoperatively examined with breast MRI\u2019 [37% vs.17.5%; OR 2.8 (95% CI 2.7\u20132.9)], the \u2018proportions of patients receiving primary systemic therapy examined with breast MRI\u2019 [83.3% vs. 70.8%; OR 2.3 (95% CI 1.3\u20133.3)], and \u2018proportion of patients receiving a single breast operation\u2019 [95.2% vs. 91.5%; OR 1.8 (95% CI 1.4\u20132.2)]. Country scores for \u2018immediate breast reconstruction\u2019 and \u2018postoperative radiotherapy after breast-conserving surgery\u2019 were comparable. The EUSOMA standard was achieved in both countries for 4\/5 indicators.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both countries achieved high scores on the QIs. Differences were observed in the use of MRI and proportion of patients receiving single surgery. The federated approach supports future possibilities on benchmark QIs without transfer of privacy-sensitive data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-06986-0","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T03:13:30Z","timestamp":1687662810000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics"],"prefix":"10.1007","volume":"201","author":[{"given":"Dave T.","family":"Hamersma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs","family":"Geleijnse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Heeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cellamare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc B. I.","family":"Lobbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A. M.","family":"Mureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linetta B.","family":"Koppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Skjerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan F.","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina G. M.","family":"Groothuis-Oudshoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-824X","authenticated-orcid":false,"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,25]]},"reference":[{"key":"6986_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/BCTT.S176070","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Salehiniya H (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer 11:151\u2013164. https:\/\/doi.org\/10.2147\/BCTT.S176070","journal-title":"Breast Cancer"},{"key":"6986_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2017.08.017","volume":"86","author":"L Biganzoli","year":"2017","unstructured":"Biganzoli L, Marotti L, Hart CD, Cataliotti L, Cutuli B, K\u00fchn T, Mansel RE, Ponti A, Poortmans P, Regitnig P, van der Hage JA, Wengstr\u00f6m Y, Rosselli Del Turco M (2017) Quality indicators in breast cancer care: an update from the EUSOMA working group. Eur J Cancer 86:59\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.017","journal-title":"Eur J Cancer"},{"key":"6986_CR3","volume-title":"Improving healthcare quality in Europe: characteristics, effectiveness and implementation of different strategies","author":"R Busse","year":"2019","unstructured":"Busse R, Klazinga N, Panteli D, Quentin W (2019) Improving healthcare quality in Europe: characteristics, effectiveness and implementation of different strategies. World Health Organization, Regional Office for Europe, Geneva"},{"issue":"1","key":"6986_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Kim HJ, Lonjon G, Zhu Y, AME Big-Data Clinical Trial Collaborative Group (2019) Balance diagnostics after propensity score matching. Ann Transl Med 7(1):16. https:\/\/doi.org\/10.21037\/atm.2018.12.10","journal-title":"Ann Transl Med"},{"key":"6986_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.09.032","volume":"104","author":"EB van Veen","year":"2018","unstructured":"van Veen EB (2018) Observational health research in Europe: understanding the general data protection regulation and underlying debate. Eur J Cancer 104:70\u201380. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.032","journal-title":"Eur J Cancer"},{"key":"6986_CR6","first-page":"870","volume":"2020","author":"A Moncada-Torres","year":"2021","unstructured":"Moncada-Torres A, Martin F, Sieswerda M, Van Soest J, Geleijnse G (2021) VANTAGE6: an open source priVAcy preserviNg federaTed leArninG infrastructurE for Secure Insight eXchange. AMIA Annu Symp Proc. 2020:870\u2013877 (eCollection 2020)","journal-title":"AMIA Annu Symp Proc."},{"issue":"3","key":"6986_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jso.24516","volume":"115","author":"AC van Bommel","year":"2017","unstructured":"van Bommel AC, Spronk PE, VranckenPeeters MT, Jager A, Lobbes M, Maduro JH, Mureau MA, Schreuder K, Smorenburg CH, Verloop J, Westenend PJ, Wouters MW, Siesling S, Tjan-Heijnen VC, van Dalen T, NABON Breast Cancer Audit (2017) Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: the national NABON Breast Cancer Audit. J Surg Oncol 115(3):243\u2013249. https:\/\/doi.org\/10.1002\/jso.24516","journal-title":"J Surg Oncol"},{"key":"6986_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijmedinf.2019.03.004","volume":"125","author":"OJ Hartmann-Johnsen","year":"2019","unstructured":"Hartmann-Johnsen OJ, K\u00e5resen R, Schlichting E, Naume B, Nyg\u00e5rd JF (2019) Using clinical cancer registry data for estimation of quality indicators: results from the Norwegian breast cancer registry. Int J Med Inform 125:102\u2013109. https:\/\/doi.org\/10.1016\/j.ijmedinf.2019.03.004","journal-title":"Int J Med Inform"},{"key":"6986_CR9","volume-title":"\u00c5rsrapport 2019 med resultater og forbedringstiltak fra nasjonalt kvalitetsregister for brystkreft","author":"Kreftregisteret","year":"2020","unstructured":"Kreftregisteret (2020) \u00c5rsrapport 2019 med resultater og forbedringstiltak fra nasjonalt kvalitetsregister for brystkreft. Kreftregisteret, Oslo"},{"key":"6986_CR10","unstructured":"IKNL (2020) Netherlands cancer registry (NCR). https:\/\/www.iknl.nl\/en\/ncr. Accessed 14 Dec 2020."},{"key":"6986_CR11","unstructured":"Norway CRO (2020) About the cancer registry. https:\/\/www.kreftregisteret.no\/en\/General\/About-the-Cancer-Registry\/. Accessed 14 Dec 2020."},{"issue":"1","key":"6986_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41","journal-title":"Biometrika"},{"issue":"3","key":"6986_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"key":"6986_CR14","volume-title":"Propensity score analysis: statistical methods and applications","author":"S Guo","year":"2014","unstructured":"Guo S, Fraser MW (2014) Propensity score analysis: statistical methods and applications. SAGE Publications, London"},{"key":"6986_CR15","unstructured":"https:\/\/github.com\/IKNL\/vtg_GLM."},{"key":"6986_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5324\/nje.v21i2.1499","volume":"21","author":"EM Jones","year":"2012","unstructured":"Jones EM, Sheehan NA, Masca N, Wallace SE, Murtagh MJ, Burton PR (2012) DataSHIELD: shared individual-level analysis without sharing the data: a biostatistical perspective. Nor J Epidemiol 21:2. https:\/\/doi.org\/10.5324\/nje.v21i2.1499","journal-title":"Nor J Epidemiol"},{"key":"6986_CR17","unstructured":"National Breast Cancer Organization of the Netherlands (2012) National guideline breast cancer 2012. NABON, Amsterdam. www.NABON.nl. https:\/\/www.nabon.nl\/wp-content\/uploads\/2022\/10\/Dutch-Breast-Cancer-Guideline-2012.pdf. Accessed Dec 2022."},{"issue":"1","key":"6986_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-007-9528-5","volume":"107","author":"RM Mann","year":"2008","unstructured":"Mann RM et al (2008) MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat 107(1):1\u201314","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6986_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-017-4117-8","volume":"162","author":"MB Lobbes","year":"2017","unstructured":"Lobbes MB et al (2017) Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Res Treat 162(2):353\u2013364","journal-title":"Breast Cancer Res Treat"},{"key":"6986_CR20","volume-title":"Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av pasienter med brystkreft","author":"NBCG","year":"2020","unstructured":"NBCG (2020) Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av pasienter med brystkreft. The Norwegian Directorate of Health, Oslo"},{"key":"6986_CR21","volume-title":"Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av pasienter med brystkreft","author":"Helsedirektoratet","year":"2007","unstructured":"Helsedirektoratet (2007) Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av pasienter med brystkreft. Helsedirektoratet, Oslo"},{"key":"6986_CR22","volume-title":"\u00c5rsrapport 2017 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft","author":"Kreftregisteret","year":"2018","unstructured":"Kreftregisteret (2018) \u00c5rsrapport 2017 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Kreftregisteret, Oslo"},{"key":"6986_CR23","unstructured":"National Breast Cancer Organization of the Netherlands (2012) National guideline breast cancer 2002. NABON, Amsterdam. www.NABON.nl. NABON, https:\/\/www.nabon.nl\/wp-content\/uploads\/2022\/11\/Richtlijn-Behandeling-Mammacarcinoom-2002.pdf"},{"issue":"3","key":"6986_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bjps.2017.12.020","volume":"71","author":"MAM Mureau","year":"2018","unstructured":"Mureau MAM, Breast Reconstruction Guideline Working Group (2018) Dutch breast reconstruction guideline. J Plast Reconstr Aesthet Surg 71(3):290\u2013304. https:\/\/doi.org\/10.1016\/j.bjps.2017.12.020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"6986_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.breast.2017.05.011","volume":"34","author":"K Schreuder","year":"2017","unstructured":"Schreuder K, van Bommel ACM, de Ligt KM, Maduro JH, Vrancken Peeters MTFD, Mureau MAM, Siesling S (2017) Hospital organizational factors affect the use of immediate breast reconstruction after mastectomy for breast cancer in the Netherlands. Breast 34:96\u2013102. https:\/\/doi.org\/10.1016\/j.breast.2017.05.011","journal-title":"Breast"},{"key":"6986_CR26","volume-title":"Subkutan mastektomi med prim\u00e6r rekonstruksjon og str\u00e5lebehandling","author":"IM Ripsrud","year":"2017","unstructured":"Ripsrud IM (2017) Subkutan mastektomi med prim\u00e6r rekonstruksjon og str\u00e5lebehandling. Springer, New York"},{"key":"6986_CR27","unstructured":"https:\/\/www.kreftregisteret.no\/Generelt\/Rapporter\/Arsrapport-fra-kvalitetsregistrene\/Arsrapport-for-brystkreft\/arsrapport-for-brystkreft-2020\/"},{"issue":"1","key":"6986_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10549-017-4232-6","volume":"164","author":"EL Vos","year":"2017","unstructured":"Vos EL, Siesling S, Baaijens MHA, Verhoef C, Jager A, Voogd AC, Koppert LB (2017) Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Res Treat 164(1):157\u2013167. https:\/\/doi.org\/10.1007\/s10549-017-4232-6","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"6986_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/a15070243","volume":"15","author":"M Cellamare","year":"2022","unstructured":"Cellamare M, van Gestel AJ, Alradhi H, Martin F, Moncada-Torres A (2022) A federated generalized linear model for privacy-preserving analysis. Algorithms 15(7):243. https:\/\/doi.org\/10.3390\/a15070243","journal-title":"Algorithms"},{"key":"6986_CR30","unstructured":"https:\/\/github.com\/IKNL\/vantage6-algorithms\/tree\/glm\/models\/glm"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06986-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T20:28:55Z","timestamp":1689971335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,25]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6986"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06986-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,25]]},"assertion":[{"value":"2 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"In addition to the above, manuscripts that report the results of studies involving humans and\/or animals should include the following declarations: This is a retrospective observational study. The Committee of Privacy of the Netherlands Cancer Registry (NCR) and the Ethics Committee of the Cancer Registry of Norway (CRN) have approved the study protocol. Approval for data use for both the pooled analysis as for the federated analysis was obtained through the regular process of data application with permission of the Committee of Privacy of the NCR (application number: K18.136_2) and the Ethics Committee of the CRN (application number: 108387).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}